These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 16164118)
1. [Flouroquinolone activity in clinical isolates of Streptococcus pneumoniae with different susceptibility to penicilline: an epidemiological study in five cities of Mexico]. Calva-Mercado JJ; Castillo G; López-Vidal Y Gac Med Mex; 2005; 141(4):253-8. PubMed ID: 16164118 [TBL] [Abstract][Full Text] [Related]
2. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804 [TBL] [Abstract][Full Text] [Related]
3. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Mather R; Karenchak LM; Romanowski EG; Kowalski RP Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779 [TBL] [Abstract][Full Text] [Related]
4. Streptococcus pneumoniae: susceptibility to penicillin and moxifloxacin. Rossi F; Franco MR; Rodrigues HM; Andreazzi D J Bras Pneumol; 2012; 38(1):66-71. PubMed ID: 22407042 [TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin]. Rodríguez-Avial I; Rodríguez-Avial C; Picazo JJ Rev Esp Quimioter; 2001 Dec; 14(4):364-8. PubMed ID: 11856983 [TBL] [Abstract][Full Text] [Related]
6. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567 [TBL] [Abstract][Full Text] [Related]
7. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci. Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781 [TBL] [Abstract][Full Text] [Related]
8. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci]. Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726 [TBL] [Abstract][Full Text] [Related]
10. Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis. Tarasi A; Capone A; Tarasi D; Cassone M; Bianco G; Venditti M J Antimicrob Chemother; 1999 Jun; 43(6):833-5. PubMed ID: 10404324 [TBL] [Abstract][Full Text] [Related]
11. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test. Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532 [TBL] [Abstract][Full Text] [Related]
12. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance. Johnson AP; Warner M; Livermore DM Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224 [TBL] [Abstract][Full Text] [Related]
13. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae. Black J; Moland ES; Chartrand SA; Thomson KS Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189 [TBL] [Abstract][Full Text] [Related]
14. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. Frémaux A; Sissia G; Geslin P J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331 [TBL] [Abstract][Full Text] [Related]
15. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones. Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243 [TBL] [Abstract][Full Text] [Related]
17. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Jacobs E; Dalhoff A; Korfmann G Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763 [TBL] [Abstract][Full Text] [Related]
19. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae. Esposito S; Noviello S; Ianniello F Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809 [TBL] [Abstract][Full Text] [Related]
20. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. White RL; Enzweiler KA; Friedrich LV; Wagner D; Hoban D; Bosso JA Diagn Microbiol Infect Dis; 2002 Jul; 43(3):207-17. PubMed ID: 12106954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]